SARS-CoV-2 Infection: What Is Currently Known about Homocysteine Involvement?

Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly throughout the world causing health, social and economic instability. The severity and prognosis of patients with SARS-CoV-2 infection are associated with the presence of comorbidities such as cardio...

Descripción completa

Detalles Bibliográficos
Autores principales: Filip, Nina, Cojocaru, Elena, Badulescu, Oana Viola, Clim, Andreea, Pinzariu, Alin Constantin, Bordeianu, Gabriela, Jehac, Alina Elena, Iancu, Cristina Elena, Filip, Cristiana, Maranduca, Minela Aida, Sova, Ivona Andreea, Serban, Ionela Lacramioara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818222/
https://www.ncbi.nlm.nih.gov/pubmed/36611302
http://dx.doi.org/10.3390/diagnostics13010010
Descripción
Sumario:Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly throughout the world causing health, social and economic instability. The severity and prognosis of patients with SARS-CoV-2 infection are associated with the presence of comorbidities such as cardiovascular disease, hypertension, chronic lung disease, cerebrovascular disease, diabetes, chronic kidney disease, and malignancy. Thrombosis is one of the most serious complications that can occur in patients with COVID-19. Homocysteine is a non-proteinogenic α-amino acid considered a potential marker of thrombotic diseases. Our review aims to provide an updated analysis of the data on the involvement of homocysteine in COVID-19 to highlight the correlation of this amino acid with disease severity and the possible mechanisms by which it intervenes.

Ejemplares similares